New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines

Disclosures: E. Guttman-Yassky received board membership from Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, Leo Pharma, AnaptysBio, Celsus, Dermira, Galderma, Novartis, Pfizer, Vitae, Glenmark, AbbVie, and Asana Biosciences and consultancy fees from Regeneron, Sanofi Aventis, MedImmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Leo Pharma, Novartis, Pfizer, Vitae, Mitsubishi Tanabe, Eli Lilly, Glenmark, and Asana Biosciences; her institution received grants from Regeneron, Celgene, BMS, Janssen, Dermira, Leo Pharma, Merck, Novartis, and UCB for other works.

Source: Annals of Allergy, Asthma and Immunology - October 13, 2019 Category: Allergy & Immunology Authors: Yael Renert-Yuval, Emma Guttman-Yassky Tags: Review Source Type: research